Deals Shaping the Medical Industry (07/2011)
Executive Summary
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
You may also be interested in...
Patent ‘March-In’ Policy Shift Will Likely Drive Uncertainty More Than Price Drops
Biden administration’s new framework will consider whether a product’s price is reasonable in deciding whether to exercise march-in rights. Numerous other factors could limit provision’s impact, but industry is concerned it will discourage firms from licensing government-funded inventions.
Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions
Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.
Edwards Plans To Boost Growth By Spinning Off Critical Care Unit In 2024
The critical care business is developing smart-recovery products integrated into Edwards’ HemoSphere monitoring platform. The company expects the tax-free transaction will help the new company advance patient monitoring technology and let Edwards focus on its structural heart technologies.